Open AccessDifferential toxicities of tyrosine kinase inhibitors in the management of metastatic lung cancer
Author(s) -
Karthik S Udupa,
Rejiv Rajendranath,
Tenali Gnana Sagar,
Joseph Thomas
Publication year - 2017
Publication title -
indian journal of medical and paediatric oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.229
H-Index - 22
eISSN - 0975-2129
pISSN - 0971-5851
DOI - 10.4103/0971-5851.203502
Subject(s) - erlotinib , gefitinib , medicine , rash , lung cancer , epidermal growth factor receptor , oncology , tyrosine kinase , erlotinib hydrochloride , pharmacology , cancer , receptor
Erlotinib and gefitinib are the most commonly used epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of EGFR mutant nonsmall cell lung cancer (NSCLC). Both erlotinib and gefitinib have shown equal efficacy in terms of response rates and overall survival. Hence, their toxicity profile becomes the most important determining factor in choosing these agents when treating EGFR mutant NSCLC. In this study, we compared the toxicity profile of erlotinib and gefitinib among an Indian subset of lung cancer patients.